巩膜胶原交联防治病理性近视的研究进展  

Research progress on pre vention and treatment of pathological myopia with scleral collagen cross-linking

作　　者：许寅聪 赵亚芳 王超英[1] 宋宏鲁 XU Yincong;ZHAO Yafang;WANG Chaoying(NO.980Hospital Of The PLA joint logistic support force,Shijiazhuang050082,China)

机构地区：[1]中国人民解放军联勤保障部队第980医院,石家庄050082

出　　处：《中国中医眼科杂志》2018年第6期404-407,共4页China Journal of Chinese Ophthalmology

基　　金：河北省卫生厅青年科技课题(20170954)

摘　　要：病理性近视已经成为国内乃至全球威胁视力健康的重要问题,目前只能通过配镜矫正、准分子激光原位角膜磨镶术(eximer laser in-situ keratomileusis, LASIK)、有晶状体眼人工晶状体植入术、后巩膜加固术来姑息矫正,但不能从根本上解决眼轴逐年延长、度数逐年增加以及各种并发症的问题。受到紫外线A-核黄素角膜交联技术应用于角膜疾病的启发,目前国内外学者积极探索巩膜胶原交联方法 ,并希望将其用于病理性近视的治疗。本文以此为出发点对核黄素-紫外线诱导巩膜胶原交联和化学交联剂结膜下注射进行巩膜胶原交联防治病理性近视的进展情况进行综述。Pathological myopia has become a significant threat to vision health in China and all over the world.At present,it can only be corrected with palliative treatments,such as wearing glasses,LASIK operation,phakic intraocular lens implantation,and posterior scleral reinforcement surgery,but these methods do not solve the fundamental problems of ocular axis length extension,degree increase and various complications over the year.Inspired by the application of ultraviolet A-riboflavin corneal cross-linking in treating corneal diseases,domestic and foreign scholars aggressively investigate scleral collagen cross-linking methods,which are expected to be used in the treatment of pathologic myopia.With this starting point,this review summarized the progress of two major scleral collagen cross-linking methods:the scleral collagen cross-linking induced by riboflavin-ultraviolet and the scleral collagen cross-linking achieved by injecting chemical crosslinking agent under the conjunctiva.

关 键 词：病理性近视 高度近视 巩膜交联 京尼平 

分 类 号：R778.11[医药卫生—眼科]